Univariable analyses for PFS and OS
| . | Patients (n) . | PFS . | OS . | ||||
|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | Number of events . | HR (95% CI) . | P . | Number of events . | ||
| Age (for 1 y increase in age) | 1.04 (1.002-1.071) | .04 | 55 | 1.06 (1.02-1.10) | .003 | 44 | |
| Age (over/ under 75 y) | over (71) vs under (68) | 1.71 (0.99-2.96) | .051 | 55 | 1.94 (1.06-3.57) | .03 | 44 |
| Rituximab Use | With (54) vs without (85) | 0.92 (0.53-1.6) | .764 | 55 | 1.05 (0.56-1.93) | .88 | 44 |
| Risk Group | High (51) vs Low (88) | 2.19 (1.28-3.73) | .004 | 55 | 2.36 (1.35-4.27) | .005 | 44 |
| Ki67 ≥ 30% | At least 30% (45) vs <30% (41) | 1.53 (0.78, 2.982) | .22 | 36 | 1.89 (0.88-4.02) | .10 | 28 |
| TP53 status | Positive (17) vs negative (29) | 2.05 (0.89-4.71) | .091 | 24 | 2.26 (0.86-5.91) | .097 | 17 |
| Blastoid/pleomorphic∗ | Yes (19) vs no (120) | 4.31 (2.32 - 8.01) | <.000001 | 55 | 3.15 (1.58-6.26) | .001 | 44 |
| sMIPI category | Low (16) vs high (67) | 1.24 (0.61- 2.56) | .54 | 55 | 1.32 (0.61-2.86) | .46 | 44 |
| Int (49) vs high (67) | 0.94 (0.52- 1.73) | .85 | 0.94 (0.48-1.84) | .84 | |||
| Stage | I-IV | 1.17 (0.76-1.81) | .48 | 1.05 (0.67-1.66) | .83 | 44 | |
| LDH ratio (pt value:upper limit of normal) | 1.95 (1.42-2.65) | <.001 | 44 | 1.83 (1.29-2.60) | <.001 | 36 | |
| LDH ratio ≥1 | Over (63) vs under (55) | 2.16 (1.20-3.89) | .01 | 50 | 2.80 (1.42-5.52) | .003 | 40 |
| WCC (continuous) | 1.001 (0.99-1.005) | .37 | 55 | 1.002 (0.999-1.006) | .256 | 44 | |
| WCC ≥10 | Over (59) vs under (74) | 0.97 (0.56-1.67) | .92 | 55 | 0.73 (0.40-1.34) | .32 | 44 |
| ECOG Performance Status binary | 2-4 (34) vs 0-1 (103) | 3.22 (1.87-5.54) | <.0001 | 55 | 3.37 (1.86 – 6.12) | <.0001 | 44 |
| . | Patients (n) . | PFS . | OS . | ||||
|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | Number of events . | HR (95% CI) . | P . | Number of events . | ||
| Age (for 1 y increase in age) | 1.04 (1.002-1.071) | .04 | 55 | 1.06 (1.02-1.10) | .003 | 44 | |
| Age (over/ under 75 y) | over (71) vs under (68) | 1.71 (0.99-2.96) | .051 | 55 | 1.94 (1.06-3.57) | .03 | 44 |
| Rituximab Use | With (54) vs without (85) | 0.92 (0.53-1.6) | .764 | 55 | 1.05 (0.56-1.93) | .88 | 44 |
| Risk Group | High (51) vs Low (88) | 2.19 (1.28-3.73) | .004 | 55 | 2.36 (1.35-4.27) | .005 | 44 |
| Ki67 ≥ 30% | At least 30% (45) vs <30% (41) | 1.53 (0.78, 2.982) | .22 | 36 | 1.89 (0.88-4.02) | .10 | 28 |
| TP53 status | Positive (17) vs negative (29) | 2.05 (0.89-4.71) | .091 | 24 | 2.26 (0.86-5.91) | .097 | 17 |
| Blastoid/pleomorphic∗ | Yes (19) vs no (120) | 4.31 (2.32 - 8.01) | <.000001 | 55 | 3.15 (1.58-6.26) | .001 | 44 |
| sMIPI category | Low (16) vs high (67) | 1.24 (0.61- 2.56) | .54 | 55 | 1.32 (0.61-2.86) | .46 | 44 |
| Int (49) vs high (67) | 0.94 (0.52- 1.73) | .85 | 0.94 (0.48-1.84) | .84 | |||
| Stage | I-IV | 1.17 (0.76-1.81) | .48 | 1.05 (0.67-1.66) | .83 | 44 | |
| LDH ratio (pt value:upper limit of normal) | 1.95 (1.42-2.65) | <.001 | 44 | 1.83 (1.29-2.60) | <.001 | 36 | |
| LDH ratio ≥1 | Over (63) vs under (55) | 2.16 (1.20-3.89) | .01 | 50 | 2.80 (1.42-5.52) | .003 | 40 |
| WCC (continuous) | 1.001 (0.99-1.005) | .37 | 55 | 1.002 (0.999-1.006) | .256 | 44 | |
| WCC ≥10 | Over (59) vs under (74) | 0.97 (0.56-1.67) | .92 | 55 | 0.73 (0.40-1.34) | .32 | 44 |
| ECOG Performance Status binary | 2-4 (34) vs 0-1 (103) | 3.22 (1.87-5.54) | <.0001 | 55 | 3.37 (1.86 – 6.12) | <.0001 | 44 |
WCC, white cell count,
Separate analysis of blastoid histology alone (ie, without pleomorphic) confirmed similar findings